FDA scrutiny on compounded medications weighs on Hims & Hers Health stock after resistance test

Traders Union
All News
Financial News
Hims & Hers Health trades flat today

Highlights

Hims & Hers Health faces increased regulatory scrutiny as seven peptides may be banned following an FDA advisory committee review July 23–24.
Novo Nordisk's lawsuit over alleged patent infringement and FDA rule circumvention adds legal and reputational risk for Hims & Hers Health.
HIMS/USD trades with pronounced bearish momentum, high intraday volatility, and a projected range of $32.01–$36.75, with downside favored.

Regulatory risk intensifies as Hims launches campaign amid lawsuits

Hims & Hers Health has launched an educational campaign on peptides ahead of an upcoming FDA advisory committee meeting scheduled for July 23–24, where seven peptides will be evaluated for possible inclusion on the Section 503A Bulks List, according to Finance Yahoo. This effort comes as the company faces greater regulatory scrutiny and aims to inform market participants about potential changes in allowable compounded ingredients, introducing increased uncertainty to the business backdrop. In parallel, Novo Nordisk is suing Hims & Hers Health for alleged patent infringement and claims of circumventing FDA safety review over compounded medications, as reported by Medicaleconomics, adding further legal and reputational risk.

Downside momentum as price meets resistance and indicators signal sell

On the hourly chart, HIMS is trading below the moving averages for 20 and 50 periods but remains positioned above the daily 200-period moving average. Immediate resistance is defined by the Ichimoku Kijun at $34.82. Momentum indicators such as the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) are in Sell territory, while the Relative Strength Index (RSI) and Commodity Channel Index (CCI) confirm persistent selling pressure. The Stochastic RSI is neutral, while Bull/Bear Power shows a clear intraday seller dominance with an oversold reading. The Awesome Oscillator stands neutral, reflecting a lack of trend confirmation, and current volatility remains elevated.

Downside risk dominates as breakout odds remain subdued

In the short term, price is expected to oscillate between $32.01 and $36.75, consistent with typical volatility for the period. The probability model assigns only a 38% chance to an upward breakout, suggesting downside risk is more likely. Baseline expectation is a sustained range within current levels, with a bullish scenario triggered if price surges above resistance at $34.82 to potentially test the upper band, and a bearish scenario if support at $32.01 fails, opening the way for further near-term declines.

Viktoras Karapetjanc, expert at Traders Union, sees a complex setup for Hims & Hers Health. He notes that regulatory and legal events raise short-term uncertainty. However, fundamental momentum in telehealth and proactive engagement with regulators supports a constructive bias. The analyst recognizes downside risk but believes broader sector trends remain resilient. "If price holds above the longer-term average and regulatory clarity emerges, I expect renewed upside attempts in the $34–$36 range."

Earlier, analysts noted that Hims & Hers Health was under selling pressure, trading below short- and medium-term moving averages while maintaining longer-term support. The current environment reinforces this cautious outlook as heightened regulatory uncertainty and new legal risks combine with persistent downside momentum, making the ability to sustain support above $32.01 especially critical for near-term stability.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.